Partnering with SFW Capital to cultivate a substantive position among CROs. Building on Sannova's stellar reputation for great relationships, good science, compliance and timeliness.

Engaged in current trials and launch of four radiotheranostics for rare cancers. Series A funded. Member of NIH I-Corps development team.

SUPPORTING STARTUPS guiding operations, planning and development for multiple early stage life science businesses:- Managing Director: Spark Insights: A premier source of accurate, actionable epidemiological data for Social Determinants of Health research. Our partner, RenovaHealth http://www.renovahealth.care engages patients in sustainable, compliant, well-documented, personal, trusted patient interviews for healthcare providers, significantly improving outcomes. Focused on rural and underserved population health.- Senior Advisor Operations : Chronic Airways Therapeutics: Commercializing innovative, proprietary oral and inhaled formulations of Nadolol and Zafirlukast for severe asthma and COPD in US & China. Recently privatized, GROWING ESTABLISHED BUSINESSES- Orchestrated strategic and tactical global development planning within a leading environmental testing/ecotox firm - Contract consultant to a major US Research Institute. Assessed preclinical business development, project management and client-focused operations to better target commercial drug developers.- Retained consultant as Senior Advisor to the CEO of Frontage Labs. Strengthened selling and business unit operations- Senior advisor to NYC based private equity firm in due diligence on two acquisition targets (ecotox & immunodiagnostics)- Partner in CRO roll-up effort consolidating 4 US biologics CROs. Surveyed and completed preliminary diligence on 35 firms. Pitched best to VCs (2012). UNIVERSITY ENGAGEMENT- Consultant to PSU Hershey Medical Center (Entrepreneur in Residence) to create in-house CRO, from underutilized braintrust and Core Labs, engaged entrepreneurship/IT/Finance students at PSU Harrisburg and Huck Institutes. - Mentored Chemistry students at Purdue Univ. and PPD students at West Chester University.

Ensured biologics identity, safety and stablity thru virology, molecular biology, process validation, analytical and microbiology testing in US, Germany, Scotland and Ireland. Related cGMP development stage biopharmaceutical manufacturing (vaccines, cell banking) businesses in the US/EU.Orchestrated major restructuring in US operations: drove material cultural, physical plant and financial performance improvements Established global team, created strategy and enlisted corporate support for investment to double revenue and capture world market leadership.Acquired NewLab Biolabs (Dusseldorf and Cologne). Integrated/harmonized operations with Pennsylvania, Edinburgh and County Mayo, Ireland sites with >400 staff.Launched and led global Six Sigma effort

Managed strategic planning and execution, M&A, P&L and integration of acquired businesses and investor relations. Created and implemented acquisition strategy – five GxP acquisitions (Phase I/IIa human clinical trials, preclinical lab, US & UK based bioanalysis labs, veterinary diagnostic instruments) including successful integration of acquired companies. Managed P&L for preclinical toxicology/pathology research services business. Increased revenue >300%. Orchestrated construction project doubling capacity. Interim CFO 2003/2004; compiled and filed SOX compliant SEC reports; renegotiated bank covenants enabling business continuance and acquisition; and orchestrated $6.5 Million sale/leaseback of Baltimore Clinical Research facility. Assistant Secretary to Board of Directors. Chaired SOX Compliance Disclosure Committee; Managed corporate Investor Relations; compiled and communicated corporate business plan; Member BASi Initial Public Offering team

Specialty formulation/packaging business.Directed worldwide sales/marketing and M&A . Created client oriented market development program exploiting distinguishing corporate characteristics, [Quality, ISO9002, employee empowerment, and automation]; Introduced seven new products in first year generating > $2 M/annum margin. Developed strategic/tactical business plan and focused growth through acquisition. Assessed multiple acquisition candidates.

Managed P&L for North/South America. Consolidated five chemical business sectors into single $62 million territorial business unit. Merged former Stauffer Intermediates group into new, global fine chemicals business (agricultural/pharmaceutical) creating >$100 million/year ICI Fine Chemicals. Upgraded and directed new product development. Three new products valued at $6M/annum.Optimized cash generation from manufacturing assets ($7 million/year cash+) by maximizing capacity utilization and developing new, low-capital products

Advanced from Process Chemist to Business Manager developing and commercializing fine chemicals for Life Sciences